Medifast Statistics
Total Valuation
Medifast has a market cap or net worth of $157.00 million. The enterprise value is $10.79 million.
| Market Cap | 157.00M |
| Enterprise Value | 10.79M |
Important Dates
The last earnings date was Tuesday, February 18, 2025, after market close.
| Earnings Date | Feb 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Medifast has 10.66 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Current Share Class | 10.66M |
| Shares Outstanding | 10.66M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 2.28% |
| Owned by Institutions (%) | 81.47% |
| Float | 9.51M |
Valuation Ratios
The trailing PE ratio is 77.53.
| PE Ratio | 77.53 |
| Forward PE | n/a |
| PS Ratio | 0.27 |
| Forward PS | 0.31 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | 9.22 |
| P/OCF Ratio | 6.41 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.57, with an EV/FCF ratio of 0.63.
| EV / Earnings | 5.16 |
| EV / Sales | 0.02 |
| EV / EBITDA | 0.57 |
| EV / EBIT | 0.70 |
| EV / FCF | 0.63 |
Financial Position
The company has a current ratio of 3.34, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.34 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.68 |
| Debt / FCF | 0.95 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 1.02% and return on invested capital (ROIC) is 4.27%.
| Return on Equity (ROE) | 1.02% |
| Return on Assets (ROA) | 3.24% |
| Return on Invested Capital (ROIC) | 4.27% |
| Return on Capital Employed (ROCE) | 6.99% |
| Revenue Per Employee | $950,257 |
| Profits Per Employee | $3,298 |
| Employee Count | 634 |
| Asset Turnover | 2.03 |
| Inventory Turnover | 3.25 |
Taxes
In the past 12 months, Medifast has paid $1.70 million in taxes.
| Income Tax | 1.70M |
| Effective Tax Rate | 44.78% |
Stock Price Statistics
The stock price has decreased by -69.90% in the last 52 weeks. The beta is 1.16, so Medifast's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -69.90% |
| 50-Day Moving Average | 16.58 |
| 200-Day Moving Average | 19.14 |
| Relative Strength Index (RSI) | 39.93 |
| Average Volume (20 Days) | 230,797 |
Short Selling Information
The latest short interest is 1.37 million, so 12.89% of the outstanding shares have been sold short.
| Short Interest | 1.37M |
| Short Previous Month | 1.39M |
| Short % of Shares Out | 12.89% |
| Short % of Float | 14.45% |
| Short Ratio (days to cover) | 6.34 |
Income Statement
In the last 12 months, Medifast had revenue of $602.46 million and earned $2.09 million in profits. Earnings per share was $0.19.
| Revenue | 602.46M |
| Gross Profit | 444.62M |
| Operating Income | 15.38M |
| Pretax Income | 37.29M |
| Net Income | 2.09M |
| EBITDA | 18.90M |
| EBIT | 15.38M |
| Earnings Per Share (EPS) | $0.19 |
Balance Sheet
The company has $162.34 million in cash and $16.13 million in debt, giving a net cash position of $146.22 million or $13.72 per share.
| Cash & Cash Equivalents | 162.34M |
| Total Debt | 16.13M |
| Net Cash | 146.22M |
| Net Cash Per Share | $13.72 |
| Equity (Book Value) | 210.11M |
| Book Value Per Share | 19.71 |
| Working Capital | 150.24M |
Cash Flow
In the last 12 months, operating cash flow was $24.48 million and capital expenditures -$7.45 million, giving a free cash flow of $17.02 million.
| Operating Cash Flow | 24.48M |
| Capital Expenditures | -7.45M |
| Free Cash Flow | 17.02M |
| FCF Per Share | $1.60 |
Margins
Gross margin is 73.80%, with operating and profit margins of 2.55% and 0.35%.
| Gross Margin | 73.80% |
| Operating Margin | 2.55% |
| Pretax Margin | 0.63% |
| Profit Margin | 0.35% |
| EBITDA Margin | 3.14% |
| EBIT Margin | 2.55% |
| FCF Margin | 2.83% |
Dividends & Yields
Medifast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.38% |
| Shareholder Yield | -0.38% |
| Earnings Yield | 1.33% |
| FCF Yield | 10.84% |
Analyst Forecast
The average price target for Medifast is $16.50, which is 12.02% higher than the current price. The consensus rating is "Hold".
| Price Target | $16.50 |
| Price Target Difference | 12.02% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medifast has an Altman Z-Score of 6.23 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.23 |
| Piotroski F-Score | 6 |